Fresenius Kabi starts United for Clinical Nutrition initiative in Europe with first-of-its-kind clinical study assessing critically ill patients in 11 European countries

Bad Homburg (ots) - The first patients are about to be enrolled in the EuroPN
survey, a clinical study that will assess the nutritional balance and focus on
functional outcomes of critically ill patients in about 100 hospitals across 11
European countries.

The survey is an important scientific project by United for Clinical Nutrition
(UFCN), a global initiative that strives to fight hospital malnutrition and its
detrimental effects on patient outcomes. Healthcare professionals in about 100
hospitals from Austria, Belgium, Czech Republic, France, Germany, Hungary,
Italy, Poland, Spain, Sweden and the United Kingdom will collect data on the
nutritional status of their patients as well as caloric and protein intake
during ICU stay. Caloric and protein balance will be related to clinical
outcomes, with a focus on measures of physical function. The collected data will
provide insights into the current practice of clinical nutrition in critically
ill patients and uncover potential to improve the quality of care.

Disease-related malnutrition can worsen clinical outcomes

In recent times, survival among critically ill patients has improved
significantly. However, disease-related malnutrition is associated with adverse
clinical outcomes, including increased risk of infections, prolonged
ventilation, and increased length of ICU stay.1 Clinical evidence suggests that
adequate nutritional intake during critical illness improves functional outcomes
and patients' quality of life after ICU discharge.2 Yet, the available evidence
- especially in critically ill patients - is still limited. The EuroPN survey
will provide valuable insights on how clinical nutrition may improve outcomes in
critically ill patients.

UFCN - a global initiative

In 2014, Fresenius Kabi established UFCN to raise awareness for disease-related
malnutrition in countries around the world. After tailoring dedicated clinical
projects and awareness campaigns for Latin America and Asia, UFCN expands their
region of interest to Europe. The current EuroPN survey marks a cornerstone of
the European initiative. For more information, please visit
www.unitedforclinicalnutrition.com.

References
1. Norman K, Pichard C, Lochs H, et al. Prognostic impact of
disease-related malnutrition Clin Nutr. 2008;27(1):5-15.
2. Wei X, Day AG, Ouellette-Kuntz H, et al. The association between
nutritional adequacy and long-term outcomes in critically ill
patients requiring prolonged mechanical ventilation: a multicenter
cohort study. Crit Care Med. 2015;43(8):1569-7.

About Fresenius Kabi

Fresenius Kabi is a global healthcare company that specializes in lifesaving
medicines and technologies for infusion, transfusion and clinical nutrition. The
company's products and services are used to help care for critically and
chronically ill patients. Fresenius Kabi's product portfolio comprises a
comprehensive range of I.V. generic drugs, infusion therapies and clinical
nutrition products as well as the devices for administering these products. In
the field of biosimilars, we focus on autoimmune diseases and oncology. In 2019,
the first biosimilar product by Fresenius Kabi was launched. Within transfusion
medicine and cell technologies, Fresenius Kabi offers products for collection
and processing of blood and cell components.

With its corporate philosophy of "caring for life", the company is committed to
putting essential medicines and technologies in the hands of people who help
patients and finding the best answers to the challenges they face.

For more information, please visit www.fresenius-kabi.com.

Contact:
For press inquiries, please contact:
Nina Espiritu
Edelman GmbH
Barmbeker Str 4, 22303 Hamburg, Germany
T: +49 (0)69 401254-345
nina.espiritu@edelman.com

Original-Content von: Fresenius Kabi Deutschland GmbH, übermittelt durch news aktuell